Understanding Biosimilar Insulins - Development, Manufacturing, and Clinical Trials

Area of Science:

• Biotechnology and Pharmaceutical Sciences
• Regulatory Science

Background:

• Expiring patents for first-generation insulin analogues enable the market entry of biosimilar insulins, which are highly similar biological products.
• Biosimilars, derived from complex biologics, are not exact copies but demonstrate significant functional and structural similarity to reference products.
• Establishing biosimilarity involves rigorous analytical, preclinical, and clinical assessments, adhering to strict regulatory guidelines from agencies like the FDA and EMA.

Purpose of the Study:

• To enhance clinical understanding of the stringent development, manufacturing, and regulatory standards governing biosimilar insulins.
• To provide insights into the evidence base required for biosimilar insulin approval.

Main Methods:

• A review of recent studies indexed in PubMed.
• Inclusion of relevant regulatory documents from major health authorities.

Main Results:

• The emergence of biosimilar insulins, driven by price competition, has the potential to broaden worldwide access to insulin analogues.
• Healthcare professionals and patients need increased awareness and confidence to fully leverage the cost benefits of biosimilar insulins.

Conclusions:

• Biosimilar insulins offer a pathway to increased global access to diabetes management tools.
• Building confidence among stakeholders is crucial for maximizing the impact of biosimilar insulin adoption and its associated cost reductions.